News Releases
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Neovasc Inc. (NVCN)
Bala Cynwyd, Pennsylvania–(Newsfile Corp. – January 17, 2023) – Law office of Brodsky & Smith announces that it is investigating potential claims…
Bala Cynwyd, Pennsylvania–(Newsfile Corp. – January 17, 2023) – Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ: NVCN) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the Company’s agreement to be acquired by Shockwave Medical, Inc. (“Shockwave”). Under the terms of the deal, Neovasc shareholders will receive US$27.25 per Common Share in cash upfront on completion of the Transaction, corresponding to an enterprise value of approximately US$100 million, plus deferred payments of up to approximately US$47 million on the achievement of future regulatory milestones in the form of a contingent value right.
The investigation concerns whether the Neovasc Board breached its fiduciary duties to shareholders by failing to conduct a fair process, and whether Shockwave is paying too little for the Company.
If you own shares of Neovasc stock and wish to discuss the legal ramifications of the investigation, or have any questions, you may e-mail or call the law office of Brodsky & Smith who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire, or Marc L. Ackerman, Esquire at Brodsky & Smith, Two Bala Plaza, Suite 805, Bala Cynwyd, PA 19004, visit https://www.brodskysmith.com/cases/neovasc-inc-nasdaq-nvcn/, or call toll free 855-576-4847.
Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/151564
nDatalyze Corp. (“NDAT” or the “Corporation”) (CSE:NDAT) (OTC:NDATF) Announces an Expansion of its YMI Validation Project
Calgary, Alberta – TheNewswire – October 17, 2023 – nDatalyze Corp. (“NDAT” or the “Corporation”) (CSE:NDAT) (OTC:NDATF) announces an expansion…
Telo Genomics Announces Clinical Launch of Non-Invasive Cancer Diagnostic, TeloViewSMM – An Important Commercial Milestone Achieved
TeloView Analyses Telomeres to Accurately Predict and Characterize Multiple MyelomaToronto, Ontario–(Newsfile Corp. – October 17, 2023) – Telo Genomics…
NervGen Pharma Appoints John Ruffolo to Board of Directors
Extensive experience in private equity, venture capital and advising high growth, innovative companiesBrings personal experience and knowledge of spinal…
